NCT06603935
Harnessing Digital Medicine to Improve Allergic Rhinitis Management in Primary Care (DMAR)
Enrolling by Invitation
NAAges 18–65InterventionalSupportive careQHSLab, Inc.
~240 participants
Updated 2026-02-09 on ClinicalTrials.gov
What's tested:QHSLab Digital Tools (AME and ARIS)
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Allergic Rhinitis Symptom Severity (SNOT-22)
Measured over Baseline, 3 months, 6 months, 12 months
Conditions
Where it's being run
1 sites across 1 statesFlorida1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Adults aged 18-65 years.
Clinically diagnosed with allergic rhinitis and/or sinusitis for at least 6 months.
SNOT-22 score of ≥20, indicating uncontrolled allergic rhinitis.
If Currently receiving treatment for allergic rhinitis and willing to continue treatment during the study.
Able and willing to provide informed consent electronically and comply with the study procedures.
Exclusion
Individuals under 18 or over 65 years of age.
Pregnant or breastfeeding women.
Recent surgical treatment for nasal polyps (within the last 3 months).
Patients with cystic fibrosis, purulent nasal infections, or any other disease likely to interfere with the study parameters.
Individuals with severe or unstable concurrent diseases or psychological disorders that may compromise participation in the study.
What this trial measures
- Change in Allergic Rhinitis Symptom Severity (SNOT-22)Baseline, 3 months, 6 months, 12 months
This outcome measures the change in allergic rhinitis symptom severity using the SNOT-22 scale. Scores range from 0 to 110, with higher scores indicating worse symptoms and lower quality of life. unit: SNOT-22 score